Duration of sodium zirconium cyclosilicate treatment and continuation of RAASi therapy after a hyperkalaemia episode

By sjmartinez • December 11, 2024

Pollack CV Jr, Arroyo D, Kanda E, Lázaro IJS, Lesén E, Franzén S, Gray CM, Lipińska A, Murohara T, Rastogi A. Duration of sodium zirconium cyclosilicate treatment and continuation of RAASi therapy after a hyperkalaemia episode. ESC Heart Fail. 2024 Dec 10. doi: 10.1002/ehf2.15171. Epub ahead of print. PMID: 39659133.

Tags: Chronic kidney disease, heart failure, hyperkalaemia, Nephrology, Potassium binder, Publications, renin–angiotensin–aldosterone system inhibitor, sodium zirconium cyclosilicate

Consensus-based Recommendations on the Management of Immunosuppression After Squamous Cell Carcinoma Diagnosis in Kidney Transplant Recipients: An International Delphi Consensus Statement

Whitley MJ, Wang JX, Chapman J, de Vries APJ, Chandran S, Glennon CM, Madariaga HM, Carroll RP, Booth J, Concepcion B, Couzi L, De Serres[...]

Metabolic Acidosis in Chronic Alcoholism: When It’s Not Just Diabetic Ketoacidosis

Li R, Han J, Sidhu H. Metabolic Acidosis in Chronic Alcoholism: When It's Not Just Diabetic Ketoacidosis. Cureus. 2025 Nov 11;17(11):e96632. doi: 10.7759/cureus.96632. PMID: 41393585;[...]

Sodium-Glucose Cotransporter-2 Inhibitors and Ketoacid Diets for Diabetic Kidney Disease

Kopple JD. Sodium-Glucose Cotransporter-2 Inhibitors and Ketoacid Diets for Diabetic Kidney Disease. Clin J Am Soc Nephrol. 2025 Dec 12. doi: 10.2215/CJN.0000000958. Epub ahead of[...]